3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Standard of Care
3
COH04S1 COVID-19 vaccine
2
remdesivir
1
palbociclib
1
ogalvibart
1
crexavibart
1
cilgavimab and tixagevimab drug combination
1
acalabrutinib
1
XAV-19
1
Therapeutics
1
Surveys and Questionnaires
1
Specimen Handling
1
Rabeprazole
1
Prednisone
1
Methylprednisolone
1
IBIO123
1
Glucocorticoids
1
Gelsolin
1
Dexamethasone
1
CVnCoV COVID-19 vaccine
1
COVID-19 Vaccines
1
COVID-19 Serotherapy
1
Atorvastatin
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
ogalvibart
×
Lymphoid
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn